ATE222104T1 - (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen - Google Patents
(imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellenInfo
- Publication number
- ATE222104T1 ATE222104T1 AT98928332T AT98928332T ATE222104T1 AT E222104 T1 ATE222104 T1 AT E222104T1 AT 98928332 T AT98928332 T AT 98928332T AT 98928332 T AT98928332 T AT 98928332T AT E222104 T1 ATE222104 T1 AT E222104T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- sup
- alkyl
- alkyloxy
- hydrogen
- Prior art date
Links
- 230000004663 cell proliferation Effects 0.000 title abstract 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 title abstract 2
- IKMMPHALUZQNMN-UHFFFAOYSA-N 3-(1h-imidazol-5-ylmethyl)-1h-quinolin-2-one Chemical class O=C1NC2=CC=CC=C2C=C1CC1=CN=CN1 IKMMPHALUZQNMN-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 33
- 125000003545 alkoxy group Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 150000002431 hydrogen Chemical class 0.000 abstract 7
- 125000001475 halogen functional group Chemical group 0.000 abstract 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- -1 amino, hydroxycarbonyl Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 125000004951 trihalomethoxy group Chemical group 0.000 abstract 1
- 125000004953 trihalomethyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4737697P | 1997-06-02 | 1997-06-02 | |
| PCT/EP1998/003182 WO1998055124A1 (en) | 1997-06-02 | 1998-05-25 | (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE222104T1 true ATE222104T1 (de) | 2002-08-15 |
Family
ID=21948611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98928332T ATE222104T1 (de) | 1997-06-02 | 1998-05-25 | (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen |
Country Status (22)
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4209472B2 (ja) | 1997-06-02 | 2009-01-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 平滑筋細胞増殖のインヒビターとしての（イミダゾール−５−イル）メチル−２−キノリノン誘導体 |
| US20020099438A1 (en) * | 1998-04-15 | 2002-07-25 | Furst Joseph G. | Irradiated stent coating |
| US20030040790A1 (en) * | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
| BR9911869A (pt) * | 1998-07-06 | 2001-03-27 | Janssen Pharmaceutica Nv | Inibidores da transferase da proteìna farnesil para o tratamento das artropatias |
| US7967855B2 (en) | 1998-07-27 | 2011-06-28 | Icon Interventional Systems, Inc. | Coated medical device |
| US8070796B2 (en) | 1998-07-27 | 2011-12-06 | Icon Interventional Systems, Inc. | Thrombosis inhibiting graft |
| ES2237125T3 (es) * | 1998-08-27 | 2005-07-16 | Pfizer Products Inc. | Derivados de quinolin-2-ona utiles como agentes anticancerigenos. |
| IL143859A0 (en) * | 1998-12-23 | 2002-04-21 | Janssen Pharmaceutica Nv | 1,2-annelated quinoline derivatives |
| EP1150973B1 (en) | 1999-02-11 | 2005-06-15 | Pfizer Products Inc. | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents |
| DE60008206T2 (de) | 1999-11-30 | 2004-12-02 | Pfizer Products Inc., Groton | Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase |
| US6844357B2 (en) * | 2000-05-01 | 2005-01-18 | Pfizer Inc. | Substituted quinolin-2-one derivatives useful as antiproliferative agents |
| JO2361B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
| ES2302106T3 (es) | 2000-09-11 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina. |
| FR2813791B1 (fr) * | 2000-09-14 | 2004-03-12 | Lafon Labor | Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale |
| WO2002024682A1 (en) | 2000-09-25 | 2002-03-28 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors |
| AU2001293829A1 (en) * | 2000-09-25 | 2002-04-02 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-((substituted phenyl)methyl)-quinoline and quinazoline derivatives |
| ATE409189T1 (de) | 2000-09-25 | 2008-10-15 | Janssen Pharmaceutica Nv | Farnesyl transferase-hemmende 6- heterocyclylmethyl-chinolin und chinazol-derivate |
| US7067531B2 (en) | 2000-09-25 | 2006-06-27 | Angibaud Patrick Rene | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives |
| AU2002214056A1 (en) | 2000-11-21 | 2002-06-03 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting benzoheterocyclic derivatives |
| US7129356B2 (en) | 2000-12-27 | 2006-10-31 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
| US6713462B2 (en) | 2001-06-21 | 2004-03-30 | Ariad Pharmaceuticals, Inc. | Quinolinones and uses thereof |
| ES2323265T3 (es) | 2001-12-19 | 2009-07-10 | Janssen Pharmaceutica Nv | Derivados de quinolina condensados en 1,8 sustituidos con triazoles unidos por el carbono como inhibidores de la farnesil-transferasa. |
| US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| AU2003223970B2 (en) | 2002-03-22 | 2008-03-06 | Janssen Pharmaceutica N.V. | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors |
| CA2481480C (en) | 2002-04-15 | 2011-04-12 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles |
| US8016881B2 (en) | 2002-07-31 | 2011-09-13 | Icon Interventional Systems, Inc. | Sutures and surgical staples for anastamoses, wound closures, and surgical closures |
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| US6638301B1 (en) * | 2002-10-02 | 2003-10-28 | Scimed Life Systems, Inc. | Medical device with radiopacity |
| EP1565187A4 (en) | 2002-11-13 | 2010-02-17 | Novartis Vaccines & Diagnostic | CANCER TREATMENT METHODS AND RELATED METHODS |
| US20050154451A1 (en) * | 2003-12-18 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
| NZ547277A (en) * | 2004-01-23 | 2009-08-28 | Janssen Pharmaceutica Nv | Substituted quinolines and their use as mycobacterial inhibitors |
| US7211108B2 (en) * | 2004-01-23 | 2007-05-01 | Icon Medical Corp. | Vascular grafts with amphiphilic block copolymer coatings |
| CA2556872C (en) | 2004-02-20 | 2015-05-12 | Chiron Corporation | Modulation of inflammatory and metastatic processes |
| BRPI0508703B8 (pt) * | 2004-03-15 | 2021-05-25 | Anormed Inc | processo para a síntese de um antagonista de cxcr4 |
| JP2007538004A (ja) * | 2004-03-18 | 2007-12-27 | ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド | シヌクレイノパチーを治療する方法 |
| WO2005089515A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
| CA2559285A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| US20050272068A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | UCH-L1 expression and cancer therapy |
| CA2559282A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| US7063720B2 (en) * | 2004-09-14 | 2006-06-20 | The Wallace Enterprises, Inc. | Covered stent with controlled therapeutic agent diffusion |
| US20060083770A1 (en) * | 2004-10-15 | 2006-04-20 | Specialty Coating Systems, Inc. | Medical devices and methods of preparation and use |
| US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
| WO2006110197A2 (en) | 2005-03-03 | 2006-10-19 | Icon Medical Corp. | Polymer biodegradable medical device |
| US20060201601A1 (en) * | 2005-03-03 | 2006-09-14 | Icon Interventional Systems, Inc. | Flexible markers |
| US20060200048A1 (en) * | 2005-03-03 | 2006-09-07 | Icon Medical Corp. | Removable sheath for device protection |
| US9107899B2 (en) | 2005-03-03 | 2015-08-18 | Icon Medical Corporation | Metal alloys for medical devices |
| US8323333B2 (en) * | 2005-03-03 | 2012-12-04 | Icon Medical Corp. | Fragile structure protective coating |
| US20060264914A1 (en) * | 2005-03-03 | 2006-11-23 | Icon Medical Corp. | Metal alloys for medical devices |
| US7540995B2 (en) | 2005-03-03 | 2009-06-02 | Icon Medical Corp. | Process for forming an improved metal alloy stent |
| KR101368519B1 (ko) | 2005-05-23 | 2014-02-27 | 노파르티스 아게 | 결정형 및 기타 형태의 4-아미노-5-플루오로-3-［6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일］-1ｈ-퀴놀린-2-온 락트산염 |
| AU2006275514B2 (en) | 2005-07-29 | 2012-04-05 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| EP1968591A4 (en) | 2005-12-23 | 2010-02-17 | Link Medicine Corp | TREATMENT OF SYNUCLEINOPATHIES |
| US20070148390A1 (en) * | 2005-12-27 | 2007-06-28 | Specialty Coating Systems, Inc. | Fluorinated coatings |
| US8404896B2 (en) | 2006-12-01 | 2013-03-26 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| CN101641339B (zh) | 2007-02-01 | 2013-07-17 | 雷斯韦洛吉克斯公司 | 用于预防和治疗心血管疾病的化合物 |
| WO2008147788A1 (en) * | 2007-05-23 | 2008-12-04 | Allergan, Inc. | Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds |
| US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| KR101629356B1 (ko) | 2008-06-26 | 2016-06-13 | 리스버로직스 코퍼레이션 | 퀴나졸리논 유도체의 제조방법 |
| US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| BRPI0920927A2 (pt) * | 2008-11-13 | 2019-09-24 | Link Medicine Corp | derivados de azaquinolinona e usos dos mesmos |
| US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| AU2010204106B2 (en) | 2009-01-08 | 2014-05-08 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
| MX2021012876A (es) | 2009-03-18 | 2022-06-23 | Resverlogix Corp | Nuevos agentes anti-inflamatorios. |
| ES2821018T3 (es) | 2009-04-22 | 2021-04-23 | Resverlogix Corp | Nuevos agentes antiinflamatorios |
| US8398916B2 (en) | 2010-03-04 | 2013-03-19 | Icon Medical Corp. | Method for forming a tubular medical device |
| PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
| RU2014136226A (ru) * | 2012-02-13 | 2016-04-10 | Ф.Хоффманн-Ля Рош Аг | Производные имидазолилкетона в качестве ингибиторов альдостеронсинтазы |
| WO2014062667A1 (en) | 2012-10-16 | 2014-04-24 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of ror-gamma-t |
| KR20150070348A (ko) | 2012-10-16 | 2015-06-24 | 얀센 파마슈티카 엔.브이. | RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제 |
| PE20150778A1 (es) | 2012-10-16 | 2015-05-23 | Janssen Pharmaceutica Nv | Moduladores de quinolinilo unidos a metileno de ror-gamma-t |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| AU2014334619A1 (en) | 2013-10-15 | 2016-04-21 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORyt |
| ES2742843T3 (es) | 2013-10-15 | 2020-02-17 | Janssen Pharmaceutica Nv | Moduladores de quinolinilo de ROR(gamma)t |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| WO2015199816A1 (en) | 2014-06-24 | 2015-12-30 | Icon Medical Corp. | Improved metal alloys for medical devices |
| WO2016100782A1 (en) * | 2014-12-18 | 2016-06-23 | University Of South Carolina | Suppression of neointimal formation following vascular surgery using cdk8 inhibitors |
| US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| KR102514971B1 (ko) | 2015-04-21 | 2023-03-27 | 아이거 바이오파마슈티컬스 인코포레이티드 | 로나파르닙 및 리토나버를 포함하는 약제 조성물 |
| PT3277842T (pt) | 2015-08-17 | 2019-09-05 | Kura Oncology Inc | Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase |
| EP3389652B1 (en) | 2015-12-14 | 2022-09-28 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| EP3389634B1 (en) | 2015-12-14 | 2021-10-06 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| SI3393468T1 (sl) | 2015-12-22 | 2023-01-31 | X4 Pharmaceuticals, Inc. | Postopki za zdravljenje bolezni imunske pomanjkljivosti |
| WO2017151548A1 (en) | 2016-03-04 | 2017-09-08 | Mirus Llc | Stent device for spinal fusion |
| CN109153722A (zh) | 2016-04-08 | 2019-01-04 | X4 制药有限公司 | 用于治疗癌症的方法 |
| CN109641838A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| CN116554168A (zh) | 2016-06-21 | 2023-08-08 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| EP3838275A1 (en) | 2016-11-03 | 2021-06-23 | Kura Oncology, Inc. | Farnesyltransferase inhibitors for use in methods of treating cancer |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| CN110204487B (zh) * | 2019-06-21 | 2021-09-28 | 江南大学 | 一种喹啉衍生物的合成方法 |
| CN113072490B (zh) * | 2021-03-26 | 2022-08-16 | 中国海洋大学 | 一种替吡法尼喹啉酮中间体的高效合成方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE456347B (sv) | 1982-02-09 | 1988-09-26 | Ird Biomaterial Ab | Ytmodifierat fast substrat samt forfarande for framstellning derav |
| US5213898A (en) | 1989-10-12 | 1993-05-25 | Norsk Hydro A.S. | Process for the preparation of surface modified solid substrates |
| US5049403A (en) | 1989-10-12 | 1991-09-17 | Horsk Hydro A.S. | Process for the preparation of surface modified solid substrates |
| US5356433A (en) | 1991-08-13 | 1994-10-18 | Cordis Corporation | Biocompatible metal surfaces |
| JPH07112930A (ja) * | 1993-10-14 | 1995-05-02 | Kyowa Hakko Kogyo Co Ltd | 血管平滑筋細胞増殖抑制剤 |
| CA2216943C (en) | 1995-04-19 | 2003-06-17 | Schneider (Usa) Inc. | Drug release coated stent |
| US5607475A (en) | 1995-08-22 | 1997-03-04 | Medtronic, Inc. | Biocompatible medical article and method |
| US5863904A (en) | 1995-09-26 | 1999-01-26 | The University Of Michigan | Methods for treating cancers and restenosis with P21 |
| TW349948B (en) * | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
| SI1162201T1 (sl) * | 1995-12-08 | 2006-08-31 | Janssen Pharmaceutica Nv | (Imidazol-5-il)metil-2-kinolinonski derivati kot inhibitorji farnezil protein transferaze |
| JP4209472B2 (ja) | 1997-06-02 | 2009-01-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 平滑筋細胞増殖のインヒビターとしての（イミダゾール−５−イル）メチル−２−キノリノン誘導体 |
-
1998
- 1998-05-25 JP JP50144099A patent/JP4209472B2/ja not_active Expired - Lifetime
- 1998-05-25 CN CNB2005101163581A patent/CN100525766C/zh not_active Expired - Lifetime
- 1998-05-25 ES ES98928332T patent/ES2182327T3/es not_active Expired - Lifetime
- 1998-05-25 BR BR9810423-3A patent/BR9810423A/pt not_active Application Discontinuation
- 1998-05-25 CN CNB98805700XA patent/CN1231215C/zh not_active Expired - Lifetime
- 1998-05-25 IL IL13321298A patent/IL133212A/en not_active IP Right Cessation
- 1998-05-25 CA CA002290992A patent/CA2290992C/en not_active Expired - Lifetime
- 1998-05-25 EP EP98928332A patent/EP0988038B1/en not_active Expired - Lifetime
- 1998-05-25 RU RU2000100032/14A patent/RU2209066C2/ru active
- 1998-05-25 AU AU80207/98A patent/AU740603B2/en not_active Expired
- 1998-05-25 DE DE69807222T patent/DE69807222T2/de not_active Expired - Lifetime
- 1998-05-25 TR TR1999/02923T patent/TR199902923T2/xx unknown
- 1998-05-25 NZ NZ501401A patent/NZ501401A/en not_active IP Right Cessation
- 1998-05-25 PT PT98928332T patent/PT988038E/pt unknown
- 1998-05-25 AT AT98928332T patent/ATE222104T1/de active
- 1998-05-25 KR KR10-1999-7010744A patent/KR100517832B1/ko not_active IP Right Cessation
- 1998-05-25 DK DK98928332T patent/DK0988038T3/da active
- 1998-05-25 WO PCT/EP1998/003182 patent/WO1998055124A1/en active IP Right Grant
- 1998-05-28 ID IDW991506A patent/ID24675A/id unknown
- 1998-06-01 ZA ZA9804700A patent/ZA984700B/xx unknown
-
1999
- 1999-05-25 US US09/445,009 patent/US6365600B1/en not_active Expired - Lifetime
- 1999-12-01 NO NO19995883A patent/NO318834B1/no not_active IP Right Cessation
-
2000
- 2000-07-08 HK HK00104198A patent/HK1025046A1/xx not_active IP Right Cessation
-
2001
- 2001-11-28 US US09/996,147 patent/US6743805B2/en not_active Expired - Lifetime
-
2003
- 2003-06-18 US US10/464,570 patent/US6734194B2/en not_active Expired - Lifetime
-
2004
- 2004-04-14 US US10/823,862 patent/US7253183B2/en not_active Expired - Lifetime
-
2006
- 2006-08-16 HK HK06109112.8A patent/HK1088820A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE222104T1 (de) | (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen | |
| EP1162201A3 (en) | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives | |
| RU2000100032A (ru) | Производные (имидазол-5-ил)метил-2-хинолинона в качестве ингибиторов пролиферации клеток гладкой мышцы | |
| PL356252A1 (en) | Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist | |
| NO931766D0 (no) | Topiske preparater for transdermal avlevering av forloeperlegemiddelderivater av morfin | |
| DE602004006165D1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
| NO981528D0 (no) | Substituerte imidazoler med antikreft- og cytokininhibitoraktivitet | |
| EE9800223A (et) | Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine | |
| UA50719C2 (uk) | Проліки для терапії пухлин і запальних захворювань | |
| PE20010541A1 (es) | Uso de una composicion de benzimidazol para tratar el cancer | |
| SE9700642D0 (sv) | Medel och sätt för förebyggande och behandling av det metabola syndromet | |
| NZ308391A (en) | Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers | |
| IS5588A (is) | Æxliseyðandi miðlar | |
| RU94044356A (ru) | Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с | |
| NO980419L (no) | Anvendelse av 1H,2,4-triazol derivater for å inhibere cancervekst | |
| ITMI922331A1 (it) | Uso di paratormone, suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione | |
| BR9915390A (pt) | Tratamento de tumores através de administração de compostos que liberam harmÈnio de crescimento e seus antagonistas | |
| BR9709556A (pt) | Dihidrobenzopirano e compostos a ele relacionados úteis como agentes antiflamatórios | |
| DK0841912T3 (da) | 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning | |
| Hattori et al. | Synergistic effect of indomethacin with adriamycin and cisplatin on tumor growth | |
| IL150787A0 (en) | Semi-synthetic taxanes with antitumor and antiangiogenetic activities | |
| BR0012502A (pt) | Inibidores da expressão do gene para interleucina 5 | |
| HUP9904578A2 (hu) | Xanomelin alkalmazása bipoláris depresszió kezelésére szolgáló gyógyszerkészítmények előállítására | |
| BR9610077A (pt) | Utilização de um composto e associação | |
| ITMI910435A0 (it) | Benzofurano-imidazoli per uso come inibitori di aromatasi e 17,20-liasi e trattamento del cancro della mammella e nell'iperplasia prostatica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0988038 Country of ref document: EP |